The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study
Background: More than half of patients with Parkinson’s disease will experience psychosis symptoms in the form of hallucinations or delusions at some point over the course of their disease. These symptoms can significantly impact patients’ health-related quality of life, cognitive abilities, and act...
Main Authors: | Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate, Victor Abler |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2024-03-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864241228350 |
Similar Items
-
Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
by: Victor Abler, et al.
Published: (2022-10-01) -
Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
by: Jamir Pitton Rissardo, et al.
Published: (2022-09-01) -
Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study
by: Mark Forman, et al.
Published: (2021-06-01) -
Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE Studies
by: Bugarski-Kirola D, et al.
Published: (2024-01-01) -
Methods of synthesis of Pimavanserin: the first drug approved for the treatment of Parkinson's disease psychosis (PDP)
by: Nader Robin Al Bujuq
Published: (2020-02-01)